<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503292</url>
  </required_header>
  <id_info>
    <org_study_id>17-011283</org_study_id>
    <nct_id>NCT03503292</nct_id>
  </id_info>
  <brief_title>Pharmacogenomics and Post-Operative Nausea and Vomiting</brief_title>
  <official_title>Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic
      data to guide post-operative nausea and vomiting treatment in the bariatric surgical
      population. The hypothesis is that using genotypic variation in CYP2D6 to select the
      appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in
      the bariatric surgical population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Episodes of postoperative nausea</measure>
    <time_frame>0-48 hours post bariatric surgery</time_frame>
    <description>Post operative nausea will be determined by nursing documentation or by treatment with rescue antinausea medication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Episodes of postoperative vomiting</measure>
    <time_frame>0-48 hours post bariatric surgery</time_frame>
    <description>Post operative vomiting will be determined by nursing documentation or by treatment with rescue antinausea medication.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Nausea</condition>
  <arm_group>
    <arm_group_label>CYP2D6 rapid metabolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CYP2D6 rapid metabolizer status will received granisetron for for post operative nausea and vomiting prophylaxis and treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 normal metabolizer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CYP2D6 poor or normal metabolizer status will received 4mg ondansetron for post operative nausea and vomiting prophylaxis and treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>Rapid metabolizer will receive 1mg IV Granisetron</description>
    <arm_group_label>CYP2D6 rapid metabolizer</arm_group_label>
    <other_name>Kytril</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>Poor or normal metabolizers will receive 4mg Ondansetron IV</description>
    <arm_group_label>CYP2D6 normal metabolizer</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  A Mayo Clinic patient scheduled to undergo any bariatric surgical procedure, including
             Roux-en-Y gastric bypass, sleeve gastrectomy, or duodenal switch.

          -  Patient age 18 or above.

          -  Patients must understand and provide written informed consent and HIPAA authorization
             prior to initiation of any study-specific procedures.

          -  Patient is willing to engage in a medication adjustment as part of their clinical
             visit (when needed).

        Exclusion Criteria

          -  Patient with uncontrolled concurrent illness including psychiatric illness, or
             situations that would limit compliance with the study requirements or the ability to
             willingly give written informed consent.

          -  Patients that deny access to their medical records for research purposes will not be
             included in this study. Also any patient who will be unable to have genetic testing at
             minimum of 1 week prior to scheduled surgery or with allergies to ondansetron or
             granisetron.

          -  Any patient with prior genetic testing that is readily available in the medical record
             will be excluded from this study.

          -  Any patient that is pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvette N Martin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shonie Buenvenida, RN</last_name>
    <phone>1-866-265-9263</phone>
    <email>Buenvenida.Shonie@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yvette N Martin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yvette N. Martin, MD-PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacogenetics</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>Ondansetron</keyword>
  <keyword>Granisetron</keyword>
  <keyword>Bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Granisetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

